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Abstract
Cdr2 is a tumor antigen expressed in a high percentage of breast and ovarian tumors and is the target of a naturally
occurring tumor immune response in patients with paraneoplastic cerebellar degeneration, but little is known of its
regulation or function in cancer cells. Here we find that cdr2 is cell cycle regulated in tumor cells with protein levels
peaking in mitosis. As cells exit mitosis, cdr2 is ubiquitinated by the anaphase promoting complex/cyclosome (APC/C) and
rapidly degraded by the proteasome. Previously we showed that cdr2 binds to the oncogene c-myc, and here we extend
this observation to show that cdr2 and c-myc interact to synergistically regulate c-myc-dependent transcription during
passage through mitosis. Loss of cdr2 leads to functional consequences for dividing cells, as they show aberrant mitotic
spindle formation and impaired proliferation. Conversely, cdr2 overexpression is able to drive cell proliferation in tumors.
Together, these data indicate that the onconeural antigen cdr2 acts during mitosis in cycling cells, at least in part through
interactions with c-myc, to regulate a cascade of actions that may present new targeting opportunities in gynecologic
cancer.
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Introduction
Cerebellar-degeneration-related antigen-2 (cdr2) is a target
antigen in paraneoplastic cerebellar degeneration (PCD), one of
several immune-mediated paraneoplastic neurologic degenera-
tions (PND) that develop as a remote effect of systemic cancers
[1,2]. In the PNDs, onconeural antigens, which are normally
expressed in immune-privileged neurons, become ectopically
expressed in tumors. PND patients typically present with
neurological symptoms while their associated tumors are usually
detected subsequently, a phenomenon believed to relate to tumor
immune-suppression [3]. It is believed that after the onset of this
appropriate tumor immune response, the immune system
becomes competent to target onconeural antigen-expressing
neurons.
PCD patients harbor breast or ovarian tumors [4] that
ectopically express cdr2, which is normally made in cerebellar
Purkinje neurons and brainstem neurons and testes [3,5]. High
titer antibodies reactive with cdr2 are found in the serum and
cerebrospinal fluid (CSF) of PCD patients and were used to clone
several candidate genes [6–8]. The only one of these genes
expressed at the protein and RNA level in tumors obtained from
PCD patients as well as in Purkinje neurons is cdr2 [5]. It is not
clear why tumor cells express onconeural antigens, since it appears
to put them at risk for immune-mediated destruction. For
example, patients with PCD harbor cdr2-specific CD8+ T cells
[9,10]. We previously reported that the PCD antigen cdr2 is
commonly expressed in gynecologic cancers in more than 50% of
ovarian tumors and 22% of breast tumors obtained from the
general population of cancer patients [4]. In addition, we have
found that cdr2 interacts with c-myc in the cytoplasm of Purkinje
neurons and that cdr2 can inhibit c-myc-dependent transcription
in tumor cell lines [11]. These observations suggested a possible
role for cdr2 in cancer cell biology.
To explore these observations further, we analyzed cdr2
expression in tumor cells and discovered that it is cell cycle
regulated, with protein levels peaking during mitosis. Cdr2 is
degraded by the proteasome during mitotic exit by a mechanism
that includes recognition and ubiquitination by the anaphase-
promoting complex/cyclosome (APC/C). We extend previous
observations demonstrating that cdr2 co-localizes and co-
precipitates with c-myc in the brain to show that it also does so
during mitosis, and that cdr2-mediated modulation of c-myc-
dependent transcription is maximal as cells passage through
mitosis. Further, we show that cdr2 is required for proper
execution of mitosis, as cdr2 knockdown cells have an increased
incidence of aberrant mitotic spindles. Cdr2 knockdown cells also
exhibit impaired proliferation, while cdr2 overexpression drives
proliferation in tumors. Taken together, these data demonstrate a
role for cdr2 in mitosis in cycling cells, and suggest that this
onconeural antigen may play a functional role in gynecologic
tumors.
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Cdr2 is expressed during mitosis
We analyzed cdr2 expression in HEK293 cells by immunoflu-
orescence microscopy using PCD patient CSF that specifically
recognizes cdr2 and a closely related family member, cdr3
[4,5,7,12]. Only a subset of HEK293 (Fig. 1A) cells exhibits high
cdr2/3 expression levels. Counterstaining with the nuclear stain
DAPI revealed that these cells are in mitosis. Confocal microscopy
with a cdr2-specific monoclonal antibody confirmed that cdr2 is
expressed in mitotic cells with a diffuse distribution not contiguous
with DNA (Fig. 1A). We found a similar pattern of staining in cells
transduced with retroviral constructs expressing T7-tagged cdr2
(Fig. 1A) but not in cells expressing vector alone. Cdr2 protein
expression levels appear highest in cells that display a rounded-up
appearance typical of mitotic cells (Fig. 1A), while neighboring
interphase cells exhibit low-level immunoreactivity.
To directly measure cdr2 protein levels during the cell cycle, we
monitored protein levels by Western blot analysis of synchronized
cells. We blocked HEK293 cells at G1/S with sequential
thymidine and aphidicolin treatment [13,14], or at metaphase
by releasing G1/S-arrested cells into demecolcine (Fig. 1B). Cdr2
immunoreactivity was ,23-fold higher during G2/M than at G1/
S, compared to a ,12-fold increase in cyclinB1, a protein known
to exhibit high expression in mitosis [15]. There was no significant
change in the levels of c-tubulin, a protein whose levels are not cell
cycle regulated (Fig. 1B).
To determine whether changes in cdr2 mRNA levels might
contribute to the observed changes in cdr2 protein expression, we
harvested RNA from HeLa cells at different time points during the
cell cycle and measured cdr2 mRNA levels by quantitative RT-
PCR (qRT-PCR). As controls, we measured cyclinB1 mRNA
levels, as these are known to decrease after mitotic exit [15], and b-
actin mRNA levels, as these do not change during the cell cycle
[16]. After release from a G2/M block, both cyclinB1 mRNA and
cdr2 mRNA levels decreased, with cdr2 levels declining 40% in 12
hours (Fig. 1C). We also observed a significant increase in cdr2
mRNA levels in cells released from G1/S blockade prior to entry
into mitosis (Fig. S1). The regulation of cdr2 mRNA levels is
consistent with the results of two microarray studies, in human
primary fibroblasts [17] and HeLa cells [16] that screened for cell
cycle regulated transcripts. In particular, the HeLa study found
that cdr2 mRNA levels peaked in G2 and were 3.4-fold higher
during early G2 relative to G1, compared with a 7.3-fold increase
in cyclinB1 mRNA. Thus, regulation of steady-state cdr2 mRNA
during the cell cycle parallels the rise and fall of cdr2 protein
during mitosis, suggesting that de novo translation of cdr2 mRNA
contributes to the increase in protein.
cdr2 protein is targeted for degradation upon mitotic
exit
To examine whether the high levels of cdr2 in mitosis are
subsequently reduced by protein turnover, we assayed whether
cdr2 protein was targeted for degradation as cells exit mitosis.
HEK293 cells were released from a mitotic block [18,19] and
harvested for Western blot analysis following exit from mitosis.
Cdr2 protein levels remain unchanged at 2 hours, but then fell
rapidly, such that they were significantly decreased (by ,80%) 8
hours after mitotic release (Fig. 1D). CyclinB1 levels also decreased
sharply following release from the block [15], while c-tubulin levels
remained unchanged under all conditions (Fig. 1D). Notably, at
the 8-hour time point, faster-migrating cdr2 immunoreactive
bands appeared (Fig. 1D). We interpreted these bands to be C-
terminal cdr2 degradation products as they are detectable in
proportion to the decrease in full-length cdr2 levels and were
specific to C-terminal cdr2 antibodies. Consistent with the rapid
degradation observed during mitotic exit, cdr2 has a short half-life
of ,1 hour in HeLa cells (Fig. S1). These studies were performed
using cycloheximide treatments since the lack of a specific cdr2-
immunoprecipitating antibody precluded us from performing
traditional pulse-chase assays. Taken together, these data indicate
that cdr2 is regulated during the cell cycle such that protein
expression is high throughout mitosis and is specifically degraded
as cells exit mitosis.
cdr2 ubiquitination and degradation
To determine whether cdr2 protein is degraded by the
proteasome, we examined the effect of MG132, a proteasome
inhibitor, on levels of T7cdr2 in HEK293 cells. MG132 treatment
for 6 hours led to a 2-fold increase in T7cdr2 protein levels
compared to vehicle-treated cells (Fig. 1E). To determine whether
cdr2 degradation may be ubiquitin-mediated, we transiently co-
transfected HEK293 cells with T7cdr2 and HA-ubiquitin
expression vectors [20]. We treated asynchronous cells with either
vehicle or MG132 followed by immunoprecipitation with anti-T7
or control antibodies (Fig. S1), and assayed immunoprecipitates for
HA-immunoreactivity. Anti-HA western blotting (Fig. 1F) of
control- or MG132-treated inputs confirmed the efficacy of the
MG132 in this experiment. In vehicle-treated cells, we observed
T7cdr2-ubiquitin conjugates ranging from 75–100 kDa (Fig. 1F),
while no HA-ubiquitin was detected in control immunoprecipita-
tions. In the presence of MG132, we observed an increase in total
immunoprecipitated T7cdr2-ubiqiutin conjugates (data now
shown) as well as an increase in the size of the T7cdr2-ubiquitin
species which ranged from ,150–275 kDa (Fig. 1F).
cdr2 KEN and destruction boxes are necessary for
efficient degradation
Ubiquitin-mediated degradation of mitotic B-type cyclins by the
anaphase-promoting complex/cyclosome (APC/C) was first
described in budding yeast [21,22]. The APC/C recognizes target
proteins harboring sequence elements termed destruction (D) and
KEN box motifs [23]. Examination of cdr2 revealed the presence
of amino acids matching consensus KEN (KENXXXN/D/E) and
D (RXXL) box motifs (Fig. 2A) clustered within an 80 amino acid
region in the C-terminal half of the protein. The 80 amino acid
region containing cdr2’s putative KEN and D boxes is highly
conserved, with 89% identity among all available mammalian
genomes, and 99% identity in mouse, rat, and human. To test
whether mutating these sequences altered cdr2 stability in cells
exiting mitosis, we compared the steady-state levels of wild type
and a mutant form of T7cdr2 (T7cdr2 KEN/D1D2) in which the
consensus KEN and D box residues were mutated to alanines
(Fig. 2A) as such mutations have been shown to abrogate KEN
and D box recognition [23,24]. We observed that T7cdr2 KEN/
D1D2 protein is expressed at 1.8-fold higher levels than wild type
T7cdr2 in HEK293 cells four hours following release from a
nocodazole block (Fig. 2B). In parallel, we performed degradation
assays in which we incubated in vitro synthesized
35S-labeled
proteins with an HEK293 extract harvested from cells exiting
mitosis. After two hours of incubation, T7cdr2 protein was
significantly more degraded than T7cdr2 KEN/D1D2 (Fig. 2C;
40% degradation for wild type compared to 20% degradation for
KEN/D1D2; (p,0.05), while cyclinB1 was degraded at the same
rate as T7cdr2.
We also compared ubiquitination of wild type and T7cdr2
KEN/D1D2 in cells exiting mitosis. We observed robust
polyubiquitination of wild type T7cdr2 in the absence of any
Cdr2 Functions during Mitosis
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lower molecular weight (,75KDa) ubiquitin conjugates were
evident in T7cdr2 KEN/D1D2 mutant extracts, which may
correspond to mono- or di-ubiquitinated cdr2 (quantitated by
densitometry; Fig. 2D). An apparent increase in the overall levels
of T7cdr2 KEN/D1D2 ubiquitination was parallel to the increase
in steady state levels of the T7cdr2 KEN/D1D2 protein (Fig. 2B
and data not shown). Taken together, these data are consistent
with enhanced stability of T7cdr2 KEN/D1D2 in cells exiting
mitosis, and suggest that the cdr2 KEN and D boxes are required
for efficient APC/C-mediated polyubiquitination and proteasomal
cdr2 degradation in cells exiting mitosis.
Figure 1. Cdr2 expressed during mitosis, ubiquitinated and degraded during mitotic exit. A. Upper panels, immunostain of HEK293s with
cdr2/3 PCD patient CSF (green). Lower left, confocal image of HeLa cells stained with anti-cdr2 (4F5). Lower middle, right, NIH3T3 cells stained with
anti-T7 either stably infected with T7cdr2 (lower middle) or vector (lower right); DAPI, all panels except upper left. Scale bars=20 mm. B. Upper left,
flow cytometry of G1/S- and G2/M-arrested HEK293s. Upper right, western blots of HEK293 G1/S and G2/M extracts probed with anti-cdr2 (NB110;
top), cyclinB1 (middle) and c-tubulin (bottom). Bottom panel, cdr2 and cyclinB1 protein quantitation, normalized here and in D to c-tubulin levels;
*p,0.001. C. cdr2 (black) and cyclinB1 (gray) mRNA levels in HeLa cells at 0, 4, 8 and 12 hours after mitotic release, measured by qRT-PCR (normalized
to b-actin mRNA). D. Left, western of HEK293s at 0, 2, 4 and 8 hours mitotic release probed with cdr2 (4F5; top), cyclinB1 (middle) and c-tubulin
(bottom) antisera. Right, quantitation of cdr2, cyclinB1 levels. E. Left, western of HEK293 extracts transfected with T7cdr2, treated with DMSO or
MG132 probed with T7 and c-tubulin antisera; right, quantitation of T7cdr2 levels normalized to c-tubulin. *p,0.005. F. Western blots of input (left)
and anti-T7 or control (GFP) immunoprecipitates (right) from HEK293s transfected with T7cdr2 and HA-ubiquitin (HA-Ub) treated with DMSO or
MG132, and probed with anti-HA.
doi:10.1371/journal.pone.0010045.g001
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PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10045Figure 2. KEN and D box mutants stabilize Cdr2. A. Cdr2 schematic depicting acidic, coiled coil (CC) and leucine zipper (LZ) motifs and KEN and
D (D1, D2) boxes. Lower panels, alignment of consensus KEN and D box motifs with human (h), mouse (m) and rat (r) cdr2 and mutants. Amino acid
residue numbers are from human Cdr2. B. Upper, HEK293s transfected with T7cdr2 or T7cdr2 KEN/D1D2, released from G2/M block and blotted with
T7 or c-tubulin antisera. Lower, quantitation of T7cdr2 and T7cdr2 KEN/D1D2 levels normalized to c-tubulin. *p,0.01. C. Upper, autoradiographs of
degradation assays of
35S-labeled cyclinB1, T7cdr2 and T7cdr2 KEN/D1D2 at indicated times. Lower, quantitation of raw cyclinB1, T7cdr2 and T7cdr2
KEN/D1D2 levels. *p,0.05. D. Left, anti-HA blot of T7 immunoprecipitates from HEK293s transfected with T7cdr2 or T7cdr2 KEN/D1D2 and HA-Ub
(see Fig. S2); right, line graph of band intensity (x-axis) for adjacent western blot and molecular weight (y-axis); T7cdr2 (blue), KEN/D1D2 (red). E. Left,
autoradiographs of
35S-T7cdr2 ubiquitination reaction with the APC/C, APC/C/HACdc20, APC/C/HACdh1, or control (Protein A beads) for indicated
times. Right, quantitation of T7cdr2-Ub conjugates.
doi:10.1371/journal.pone.0010045.g002
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To directly test whether cdr2 is a target of the APC/C, we
immunoprecipitated the APC/C from synchronized HEK293
cells exiting mitosis and incubated the complex with in vitro
translated
35S-T7cdr2. We confirmed the efficacy of the APC/C
immunoprecipitation by blotting for three APC/C components:
cdc27, cdc23 and APC11 (Fig. S2). In the presence of the APC/C,
we observed robust ubiquitination of T7cdr2 within 20 minutes
(,3 fold over baseline levels), which increased further by 60
minutes (,5 fold), with a reciprocal decrease in full length T7cdr2
as the reaction progressed (Fig. 2E). T7cdr2 was not ubiquitinated
in the absence of added APC/C. We further demonstrated the
specificity of this assay, showing that the APC/C ubiquitinated the
canonical substrate cyclinB1, but not an unrelated onconeural
antigen, Nova1 (Fig. S2).
From metaphase until the end of G1, cdc20 and cdh1
sequentially activate the APC/C promoting binding to and
ubiquitination of D and KEN box-containing proteins, targeting
them for proteasomal degradation (/reviewed in/ [25]). To test
whether the APC/C co-activators cdc20 and cdh1 could enhance
APC/C-mediated ubiquitination of T7cdr2, immunoprecipitated
HACdc20 or HACdh1 (Fig. S2) were added to the in vitro APC/C
ubiquitination reaction. We found that addition of either cdc20 or
cdh1 enhanced APC-mediated ubiquitination of T7cdr2 by 10–
20% (Fig. 2E). Consistent with our interpretation that the T7cdr2
KEN/D1D2 mutant is ubiquitinated less efficiently in cells
(Fig. 2D), we observed that the while the APC/C could still
ubiquitinate the KEN/D1D2 mutant in vitro, it did so at reduced
levels (data now shown). Taken together, these data indicate that
cdr2 levels accumulate upon entry into mitosis and levels are then
tightly controlled by turnover during mitotic exit by APC/C-
induced polyubiquitination and proteasomal degradation.
Cdr2 is important for proper spindle formation
Based on the mitotic-enriched expression and cell cycle
regulation of cdr2 we hypothesized the cdr2-deficient HeLa cells
may be impaired in the proper execution of mitosis. Consistent
with a mitotic role for cdr2, we observed that NCBI’s conserved
domain database [26] found significant (p=5610
25) homology
between the cdr2 N-terminal coiled-coil/leucine zipper domain
and the coiled-coil regions of the structural maintenance of
chromosomes (SMC) family of proteins [27]. While the overall
identity between the respective domains is not high, the similarity
is and the homology to both prokaryotic and eukaryotic SMC
proteins is well conserved in mammalian as well as avian,
amphibian and teleost cdr2. To test whether cdr2 may be
important in mitosis, we performed cdr2 knockdown utilizing a
pool of 4 cdr2-specific siRNAs that reduced cdr2 mRNA or
protein levels (Figs. 3A, 3B, S3) to less than 10% of control siRNA-
treated HeLa cells.
To examine mitotic cells after cdr2 knockdown, we imaged
mitotic spindles in these cells by immunofluorescence microscopy,
using a a-tubulin antibody and DAPI to visualize mitotic cells.
While cdr2 knockdown in HeLa cells did not lead to overt cell
cycle arrest (Fig. S3), we observed an increase in the number of
multipolar spindles (Fig. 3C). Quantitation of this data revealed
that 21% of cdr2 knockdown cells showed aberrant multipolar
spindles 48 hours after cdr2 siRNA transfection (Fig. 3D),
compared to 11% of control cells. We note that our observation
of low-level multipolar spindle formation in control siRNA-treated
HeLa cells is consistent with previous reports [28,29].
cdr2 interacts with and regulates c-myc during mitosis
Previous studies [11] have shown that cdr2 interacts with c-myc
in vivo in the cytoplasm of Purkinje neurons. Cdr2 overexpression
Figure 3. Multipolar spindle defects in cdr2 knockdown cells. A. Quantitation of cdr2 protein normalized to c-tubulin in HeLa extracts
transfected with control or cdr2 siRNAs probed with anti-cdr2 (4F5) and anti-c-tubulin (inset). B. qRT-PCR of cdr2 mRNA normalized to b-actin mRNA
in control or cdr2 siRNA treated cells. C. Immunostain of mitotic control (left) and cdr2 knockdown (right) HeLa cells with a-tubulin antisera and DAPI;
Scale bar=20 mm. D. Quantitation of multipolar spindles in control and cdr2 knockdown cells.
doi:10.1371/journal.pone.0010045.g003
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although how the cytoplasmic cdr2 protein bound nuclear
localized c-myc in this setting was unclear. The observation that
cdr2 protein levels peak during mitosis suggested the possibility
that it might gain access to c-myc during the breakdown of the
nuclear envelope that occurs early in mitosis. To assess whether
cdr2 and c-myc colocalize during mitosis, we performed confocal
microscopy on HeLa cells. During interphase cdr2 levels were
barely detectable and localized to the cytoplasm, while c-myc was
localized exclusively to the nucleus (Fig. 4). In contrast during
mitosis, cdr2 levels were significantly higher and was co-localized
with c-myc protein that had redistributed away from DNA (Fig. 4).
High power confocal analyses confirmed the cdr2-c-myc coloca-
lization during mitosis (Fig 5A–H). While both cdr2 and c-myc
displayed diffuse staining patterns that did not overlap with the
DAPI signal, we noted that the bulk of the colocalized cdr2 and c-
myc preferentially localized proximal to the spindle poles (Fig. 5A–
D) consistent with prior observations made on c-myc alone [30].
Following completion of mitosis, c-myc re-localized to the nucleus
while cdr2 localized to the cytoplasm (Fig. 5E-H). We previously
demonstrated that cdr2 and c-myc co-immunoprecipitated in
mouse brain extracts, as well as in tissue culture cells [11]. To test
whether cdr2 and c-myc could physically interact during mitosis,
we performed co-immunoprecipitations of HeLa cells transiently
transfected with tagged cdr2 and c-myc expression constructs.
After transfection, we synchronized HeLa cells in G1/S or G2/M
and performed either c-myc or control immunoprecipitations
followed by western blots to detect cdr2 protein. These
experiments (Fig. 5I) demonstrated a direct interaction between
cdr2 and c-myc is preferentially evident during G2/M-phase, as
compared to G1/S, and support the conclusion that cdr2 binds to
c-myc when c-myc is not in contact with DNA. The preferential
interaction of cdr2 and c-myc during G2/M in this experiment
does not appear to be due to elevated levels of endogenous cdr2
protein during G2/M since transfected cdr2 was present at similar
levels during G1/S and G2/M in these experiments (data not
shown).
cdr2 regulates c-myc target genes in tumor cells
We previously demonstrated that cdr2 could inhibit c-myc-
dependent transcription in overexpression experiments [11]. To
test whether cdr2 could regulate c-myc target genes, we performed
loss-of-function siRNA knockdown studies in HeLa cells. We first
tested whether cdr2 knockdown could affect output from a c-myc
responsive E-box-luciferase reporter. HeLa cells were transfected
with the E-box-luciferase reporter, cdr2 siRNAs or control
siRNAs, and an EGFP expression construct for normalization
[11] followed by synchronization at the G1/S border. Following
release from a G1/S block, we harvested cells and assayed
luciferase activity, and we monitored the cell cycle profile by flow
cytometry. We observed a significant spike in E-box-luciferase
reporter activity 12 hours after release into S phase, which
correlated with the peak of cells in late G2/M (Fig. 5J, black bars
and data not shown), and with a prior report that c-myc-
dependent transcription spikes in late G2 [31]. Further, we found
that cdr2 knockdown led to a decrease in E-box-luciferase reporter
activity that was maximal as cell passaged through mitosis (Fig. 5J).
While the E-box luciferase reporter can also be responsive to
transcription factors other than c-myc, this observation led us to
further analyze cdr2 regulation of c-myc dependent transcription.
To assess whether cdr2 could regulate endogenously expressed
c-myc target genes in HeLa cells, we compared the transcriptional
profile of cells in the presence or absence of cdr2 using siRNA
knockdown 3 hours after release from a mitotic block. Because
there is a general shutdown of transcription during mitosis [32],
these studies likely reflect a combination of cdr2-dependent
changes in target gene expression at G2/M and M/G1 transitions.
We identified 324 cdr2-regulated genes whose expression was
changed by 1.5 fold or greater (Table S2). A gene ontology analysis
of this data set revealed enrichment for genes involved in
chromosomal, chromatin and nucleosome regulation as well as
in cell cycle and mitotic biology (Table S1).
To assess whether cdr2 could affect c-myc target gene
expression, we cross-referenced the 324 cdr2-regulated genes
(Fig. 6A) with two different c-myc target gene lists, one a
Figure 4. Cdr2 colocalizes with c-myc during mitosis. Low power (20X), thin section confocal images of HeLa cells stained with anti-c-myc
(9402; A, D), anti-Cdr2 (4F5; B, E) and merged images (C, F). Arrows denote nuclear localized c-myc; arrowhead indicates mitotic cells with co-localized
c-myc and cdr2. Scale bar=20 mm.
doi:10.1371/journal.pone.0010045.g004
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org) and the other a list of c-myc target genes identified by
chromatin immunoprecipitation (ChIP) in HeLa cells [34]. This
analysis generated two lists of putative cdr2-regulated c-myc target
genes. A Fisher’s exact test revealed that the observed degree of
overlap was highly significant for both data sets; 44 genes
overlapped (p=7.4610
211, odds ratio=3.4) with the c-myc cancer
gene database and 31 genes overlapped with the c-Myc ChIP list
(p=3.2610
27, odds ratio=3.0). We independently validated
changes in the steady state levels of 30/44 (68%) of these transcripts
from both lists by qRT-PCR (Fig. 6B; Table 1).
To investigate how cdr2 might be regulating these transcripts,
we focused on 15 well-studied genes which are known to be either
activated or repressed by c-myc and which have been previously
validated (in c-myc null cells, chromatin immunoprecipitation or
nuclear run-on experiments; [33,35]). For 13/15 (87%) of these
transcripts, cdr2 acted as an agonist of c-myc function (Table 2). In
roughly half of these cases, c-myc acts as a transcription inducer
Figure 5. Cdr2 interacts with and regulates c-myc during mitosis. High power (63X), thin section confocal images of HeLa cells stained with
anti-c-myc (9402; A, E), anti-Cdr2 (4F5; B, F), DAPI (C, G) and merged images (D, H); Scale bar=20 mm. I. Immunoprecipitation of G1/S and G2/M-
arrested V5cdr2 and c-myc transfected HeLa extracts with anti-c-myc (C3956) and control anti-HA, blotted with anti-V5 to detect co-
immunoprecipitated V5cdr2. Middle, control anti-c-myc (9E10) western of above inputs, immunoprecipitates and supernatants. Bottom, quantitation
of V5cdr2 co-precipitated by anti-c-myc, normalized to V5cdr2 input (data not shown); *p,0.01. J. Luciferase assay of G1/S released HeLa extracts
transfected with c-myc responsive E-box luciferase and cdr2 or control siRNA pools; *p,0.05.
doi:10.1371/journal.pone.0010045.g005
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of c-myc to activate some genes via an E-box, and to repress
others, for example, through actions on cell cycle genes through
binding to INR sequences [36,37]). Figure 6B shows examples of
c-myc target mRNAs that are either down-regulated or up-
regulated in the absence of cdr2.
To evaluate whether cdr2 action on c-myc target genes was
directly dependent on c-myc, we examined the effect of cdr2
knockdown in a Rat-1 c-myc null cell line [38]. We undertook
microarray experiments in wild type Rat-1 cells and c-myc-null
cells exiting mitosis that were treated with cdr2 or control siRNA
pools (Fig. S4). We identified four genes (CDKN1A, GBP2,
INHBA, TGFB2) of the 30 validated cdr2-regulated c-myc target
genes in HeLa cells that were also represented on the rat
microarray. Microarray and qRT-PCR studies revealed that three
of these genes, CDKN1A, GBP2 and TGFB2, are regulated by
cdr2 in wild type Rat-1 cells but not in c-myc null cells (Fig. 6C),
suggesting that these three genes require c-myc to show cdr2
effects on gene regulation. INHBA was not found to be cdr2-
regulated in wild type Rat-1 cells.
Several validated cdr2-regulated c-myc target genes (CCNB1,
CDCA3, CENPA, KIF15, NDC80 and NUF2) are mitosis-related
mRNA’s (Table 3) that are also down-regulated in the absence of
cdr2. Moreover, four of these genes (CENPA, KIF15, NDC80 and
NUF2) are involved in kinetochore and spindle biology (reviewed
in [39]). Additionally, cdr2 knockdown lead to a decrease (Table 3)
in four other transcripts (AURKA, CENPE, SPC25 and TTK),
which are involved in kinetochore and spindle biology, but are not
known to be c-myc targets genes ([40] and reviewed in [41]).
Although our data do not rule out the possibility that cdr2 could
have some indirect actions on c-myc target genes, collectively, the
data strongly support a model (see Discussion) whereby cdr2
interacts with c-myc during mitosis, but not during other stages of
the cell cycle, to promote downstream actions of c-myc on
transcriptional targets that mediate effects on mitotic spindle
assembly and mitotic passage.
Cdr2 regulates cellular proliferation
Our findings of a functional interaction between cdr2 and c-
myc in mitosis, together with the fact that cdr2 is expressed in
gynecologic [4] and renal [42] tumors raised the question whether
cdr2 can promote tumor growth. Remarkably, several validated
cdr2-regulated c-myc target genes in HeLa cells have roles in cell
cycle biology (Table 1, Fig. 6B). Specifically, of the c-myc target
genes that are increased following cdr2 knockdown, several are
known to inhibit the cell-cycle (CDKN1A, CDKN2B, and
TGFBR2; Table 2 and [33]). These genes are normally repressed
by c-myc, as c-myc is promoting the cell cycle and driving
proliferation. In contrast, some cell cycle-promoting genes such as
CCNB1 and CCND1, which are known to be up-regulated by c-
myc, are down-regulated following cdr2 knockdown (Table 2).
Taken together, the data form a coherent hypothesis—that cdr2
Figure 6. Cdr2 knockdown causes mis-regulation of endogenous c-myc target genes. A. Venn diagrams of microarray data of control and
cdr2 siRNA-treated HeLa cells that recently exited mitosis. Upper, 44 genes overlap between 324 cdr2-regulated genes and 1773 c-myc target genes;
lower, 32 genes overlap between cdr2-regulated genes and 1351 c-myc ChIP HeLa targets. B. qRT-PCR of select cdr2-regulated c-myc target genes
that are decreased (left) and increased (right) following cdr2 knockdown (see Table 1); *p,0.05, **p,0.005, ***p,0.0001. C. Microarray and qRT-PCR
analyses of three cdr2-regulated c-myc target mRNAs in wild type and c-myc null Rat-1 cells; *p,0.05, **p,0.005.
doi:10.1371/journal.pone.0010045.g006
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promote cellular proliferation, and that this action is inhibited by
cdr2 knockdown.
This hypothesis prompted us to ask whether cdr2 could regulate
cellular proliferation. Using
3H-thymidine incorporation to assay
steady state proliferation, we found that cdr2 knockdown led to a
14% (p,0.05) decrease in HeLa cell proliferation (Fig. 7A). We
obtained similar results (25% reduction, p,0.05) in the MCF7
breast cancer cell line (Fig. 7B), which also expresses cdr2 [10]. In
addition, cdr2 knockdown HeLa cells exhibit delayed kinetics
entering into S phase following a G1/S arrest (Fig. 7C), with the
largest reduction in proliferation observed four hours following
release.
Because cells lacking cdr2 exhibit impaired proliferation, we
tested whether cdr2 overexpression could promote cell cycle
progression in tumors. We transfected T7cdr2 into EL4
lymphoblastoid cells that have undetectable cdr2 protein levels
[10] in order to generate a stable T7cdr2-expressing clonal cell line
(EC2-1), (Fig. 8A). When compared to EL4 cells, EC2-1 cells
exhibited 1.3-fold higher steady state
3H-thymidine incorporation
(Fig. 8B) suggesting that T7cdr2 overexpression may drive the cell
cycle. We obtained similar results in both NIH3T3 cells stably
over-expressing T7cdr2 and cerebellar granule cell neurons
transiently over-expressing T7cdr2 (Fig. S5).
To evaluate whether cdr2 overexpression has growth-promoting
activity in vivo, we injected parent EL4 and EC2-1 cells into the
flanks of nude mice and monitored tumor growth over the course
of two weeks. Importantly, cdr2 expression was maintained in 4
out of the five EC2-1 tumors (Fig. 8C) for up to two weeks in the
absence of any drug selection. While we did not observe any
significant differences in tumor growth rate nor in tumor size
(Fig. 8B) before animals were sacrificed, the cdr2 positive EC2-1
derived tumors exhibited a significant increase in the number of
mitotic figures compared to that of the EL4 cell-derived tumors
(Fig. 8F). This result is consistent with the elevated proliferation
observed in vitro with EC2-1 cells. We also assessed the degree of
apoptotic death in these cells, since cells may respond to c-myc
over-activation by undergoing programmed cell death [43].
Consistent with our observation that the predominant action of
cdr2 was to promote c-myc activity, we observed an increase in the
incidence of apoptotic figures (Fig. 8G) in the EC2-1 tumors
relative to EL4 tumors. While we did not observe that cdr2
promoted c-myc-dependent transcription of apoptotic genes, these
data may provide a plausible explanation for why cdr2
overexpression in EC2 cells led to an increase in cell cycling yet
EC2-1 tumors were not larger than the control EL4 tumors.
Discussion
We have found that the paraneoplastic cerebellar degeneration
related antigen cdr2 acts as a mitotic protein in tumor cells.
Normally cdr2 expression is mostly restricted within the brain to
post-mitotic Purkinje neurons [5,11], raising the question of
whether its role in mitosis is a novel function of the protein or a
reflection of its normal neuronal biology. Many links have been
made between the cell cycle machinery and neuronal biology since
the discovery of oncogenes—for example, the ras [44] and myc
proteins [11,45] are expressed in Purkinje neurons, and the cell
cycle protein cdk5 is involved in dendrite formation [46] Thus the
evolving idea that cell cycle pathways are utilized for parallel
pathways in dividing cells and neurons is supported by the finding
here that the Purkinje protein cdr2 functions in mitotic control in
tumor cells.
Cdr2 levels are regulated in mitosis both by de novo expression of
the transcript and protein (Fig. 1), and through down-regulation at
least in part by APC/C-mediated ubiquitination and proteasome
degradation. Cdr2 levels are high in brain, raising the question of
whether cdr2 is regulated in a similar manner in neurons. The
APC/C is active in brain extracts and components of the APC/C
(APC2, Cdc27 and Cdh1), are believed to be expressed solely in
the nucleus in the cerebellum [47], while cdr2 is cytoplasmic in
Purkinje neurons, suggesting that cdr2 may escape APC/C-
mediated ubiquitination. However, recent papers have ascribed
axonal and dendritic roles to Cdh1 [48] and Cdc20 [49],
respectively, which could have relevance to cdr2, which is present
in the neuronal cytoplasm and proximal dendrites [5,11]. More
generally, the role we observe for cdr2 in mitosis and spindle
formation in dividing cells may reflect a role for cdr2 in Purkinje
neuronal dendritic remodeling, as such a role has been proposed
for the APC/C
Cdc20 in neurons [49].
Our results also suggest specific consequences for cdr2 mitotic
expression in gynecologic cancers, and thereby address the
Table 1. Validated cdr2-regulated c-myc target genes.
Gene Array qPCR MYC DB Myc ChIP
1 TGFBR2 1.7 5.59 Y
2 COL3A1 1.8 5.02 Y
3 CTGF 2.39 3.91 Y
4 INHBA 3.7 2.58 Y
5 CDKN2B 1.62 2.37 Y
6 CDKN1A 1.63 1.93 Y Y
7 SERPINE1 1.86 1.82 Y
8 GBP2 1.76 1.7 Y
9 TGFB2 1.5 1.54 Y Y
10 SERPINE2 1.79 1.43 Y
11 S100A2 1.61 1.43 Y
12 IMPDH1 0.32 0.34 Y Y
13 CDC25A 0.46 0.44 Y Y
14 HMOX1 0.62 0.54 Y
15 ERO1L 0.49 0.6 Y
16 CXCL2 0.58 0.62 Y
17 CCND1 0.56 0.63 Y
18 ETS2 0.59 0.63 Y Y
19 DPY30 0.57 0.67 Y
20 MASA 0.59 0.69 Y Y
21 PGK1 0.63 0.7 Y Y
22 RBBP4 0.6 0.71 Y Y
23 ASNS 0.61 0.72 Y
24 CCNB1 0.62 0.74 Y Y
25 DKC1 0.63 0.79 Y
26 NUF2 0.55 0.41 Y
27 CENPA 0.55 0.42 Y
28 NDC80 0.45 0.63 Y
29 CDCA3 0.39 0.64 Y
30 KIF15 0.55 0.69 Y
The table lists 30 validated cdr2-regulated c-myc target genes. Cdr2 knockdown
microarray and qRT-PCR data are indicated for each gene; values .1 indicate
up-regulation, values ,1 down-regulation. Y indicates whether the gene is
present in the c-myc cancer gene or c-myc ChIP date sets.
doi:10.1371/journal.pone.0010045.t001
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fact that this allows them to be targeted by the immune system [9].
Mechanistically, APC/C dysfunction in these tumors may play a
role; such dysfunction has been proposed to be a hallmark of
malignant tumors, as mitotic APC/C substrates were significantly
up-regulated in malignant versus non-malignant human cancers in
a survey of more than 1600 benign and malignant tumors [50].
Interestingly, we note that human cdr2 is reported to harbor cell
cycle-regulated phosphorylation sites (/PhosphoSitePlus, www.
phosphosite.org/[51]) adjacent to one of its destruction boxes.
These sites, serines 309–311, are immediately C-terminal to the
second destruction box (RKPL, 303–306aa, Fig. 2), and two of
these sites, serines 309 and 311, are phosphorylated in HeLa cells
during G1 but not during mitosis [51]. Together with the data
presented here and with the proximity of these sites to the
destruction box, we suggest a model whereby cdr2 phosphoryla-
tion at serines 309–311 might lead to enhanced APC/C-mediated
ubiquitination and subsequent degradation during G1, but not
during mitosis when these sites are un-phosphorylated and when
cdr2 levels are at their peak. Consistent with this model, our
previous observation that c-myc preferentially co-immunoprecip-
itated in vivo with a faster-migrating and possibly unphosphorylated
cdr2 species [11] suggests that the cdr2:c-myc interaction may be
favored when cdr2 is un-phosphorylated during mitosis.
We find that inappropriate expression of cdr2 in tumor cells can
impact c-myc activity. The cdr2-c-myc interaction is specific and
mediated by the cdr2 leucine zipper/coiled-coil domains [11].
Further, we find that this interaction occurs during mitosis (Figs. 4,
5) and in Rat-1 cells cdr2 acts synergistically with c-myc to regulate
endogenous c-myc target genes (Fig. 6C). And while CDKN1A’s
effects in HeLa cells would be expected to be at least partially
blocked by the HPV protein E7 [52], we note that the set of cdr2-
regulated c-myc target genes in both Rat-1 and HeLa cells
(Figs. 6B, 6C, Table 1), including the mitosis-related mRNAs
(Table 3), encode proteins important for cell cycle progression.
Also, given the recent finding that c-myc controls the expression of
two mitotic spindle-associated proteins in breast tumor cell lines
[53], our data that cdr2 may impinge on c-myc regulation of other
mitosis-related transcripts during the G2/M transition in HeLa
cells is consistent with a role for c-myc during G2 [31]. While
further experiments are needed to clarify cdr2 function in spindle
biology and whether those effects are independent of or connected
to cdr2 regulation of c-myc-dependent transcription, these
observations suggest a model (Fig. 9) in which cdr2 acts during
mitosis, in part through interactions with c-myc, to regulate a
cascade of actions related to tumor cell growth.
These findings have several implications for gynecologic cancer.
Cdr2 is not expressed at high levels outside of the brain and testis,
but is expressed in 60% of ovarian and 22% of breast tumors and
in many transformed cell lines [4,10]. Our data suggests that cdr2
may contribute to tumorigenesis, since cdr2 expression levels
Table 2. Well-studied, validated cdr2-regulated c-myc target genes.
Gene Myc Regulation Array qPCR Cdr2 Regulation Predicted cdr2 action on c-myc
1 HMOX1 D 0.62 0.54 U inhibit
2 GBP2 D 1.76 1.7 D activate
3 CDKN1A D 1.63 1.93 D activate
4 CDKN2B D 1.62 2.37 D activate
5 INHBA D 3.7 2.58 D activate
6 CTGF D 2.39 3.91 D activate
7 TGFBR2 D 1.7 5.59 D activate
8 IMPDH1 U 0.32 0.34 U activate
9 CCND1 U 0.56 0.63 U activate
10 DPY30 U 0.57 0.67 U activate
11 PGK1 U 0.63 0.7 U activate
12 ASNS U 0.61 0.72 U activate
13 CCNB1 U 0.62 0.74 U activate
14 DKC1 U 0.63 0.79 U activate
15 S100A2 U 1.61 1.43 D inhibit
The table lists 15 genes that are either up-regulated (U) or down-regulated (D) by c-myc and have been previously independently validated. For 13/15 of these mRNAs
(#’s 2-14), cdr2 appears to activate c-myc function, while for 2/15 genes (#’s 1 and 15) cdr2 appears to inhibit c-myc function.
doi:10.1371/journal.pone.0010045.t002
Table 3. Cdr2-regulated mitotic genes.
Gene Array qPCR
c-myc ChIP
(HeLa) Kinetochore Spindle
NUF2 0.55 0.41 Y Y
CENPA 0.55 0.42 Y Y
NDC80 0.45 0.63 Y Y
CDCA3 0.39 0.64 Y
KIF15 0.55 0.69 Y Y
CCNB1 0.61 0.73 Y
CENPE 0.46 0.44 Y
SPC25 0.62 0.54 Y
TTK 0.59 0.63 Y
AURKA 0.63 0.78 Y
List of 10 mitosis-related mRNAs from the 324 cdr2-regulated genes data set.
Cdr2 knockdown microarray and qRT-PCR data are indicated for each gene;
values ,1 indicate down-regulation. Y indicates whether the gene is on the c-
myc ChIP list and whether it is involved in kinetochore or spindle function.
doi:10.1371/journal.pone.0010045.t003
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tumor growth mediated by cdr2 in EL4 tumor cells, a random
screen for focus-forming genes in NIH3T3 cells [54] categorized
cdr2 as ‘‘moderately’’ oncogenic. It may be that the oncogenic
potential of cdr2 can be offset by the ability to trigger apoptotic
death, as has been noted for c-myc [43]. Our findings of a function
for cdr2 in tumor cell mitosis, together with its normally restricted
tissue expression, suggest that it may serve as a tumor target with
potential for a high therapeutic index of action.
Materials and Methods
Plasmids
We used the Rapid DNA Ligation Kit (Roche) for ligations.
Point mutations were made with the QuikChange Kit (Strata-
gene). Primers (Table S3) were synthesized by Operon. Mark
Kirschner (Harvard) provided the HACdc20, HACdh1 and
CyclinB1 vectors; Dirk Bohmann (U. of Rochester) provided the
HAUbiquitin construct; and Mary Hatten (Rockefeller University)
provided the pCXiBSR vector.
RNA, RT-qPCR
RNA was extracted using the RNeasy Kit (Qiagen). RT-qPCR
was performed as described previously [55]. PCR conditions were
determined independently for each primer pair using a temperature
gradient followed by melting curve and we also calculated the
amplification efficiency for all primer pairs. The relative amount of
initial mRNA copies was determined using the Pfaffl method [56].
Cell culture, synchronization, transfections
All cell lines were maintained at 37uC/5% CO2 in DMEM
(Mediatech), 10% fetal bovine serum (Gemini) and pen-strep
(50 U/ml; Invitrogen). Rat-1 TGR (wild type) and Rat-1 15.19 (c-
myc null) cells were a gift from Michael Cole (Dartmouth).
Cerebellar granule neurons were cultured according to established
protocols [57]. We synchronized cells by sequential thymidine/
aphidicolin block [14]. For mitotic arrest, thymidine/aphidicolin
were released in media with 0.1 mg/ml demecolcine or 0.8 mM
nocodazole. For mitotic release, nocodazole-treated cells were
washed and allowed to grow as indicated. Half of the cells were
used for flow cytometry and half for Western or RNA analysis.
Nocodazole, demecolcine, thymidine, aphidicolin and cyclohexi-
mide were from Sigma. Transfections were performed using
Fugene6 (Roche) or Lipofectamine2000 (Invitrogen).
siRNA experiments were done using non-targeting control, and
human or rat cdr2 siRNA pools (Dharmacon). Pilot experiments
demonstrated that potential off-target effects observed with high
concentrations of single siRNAs were not seen when we used
siRNA pools at low nanomolar siRNA concentrations (data not
shown). 40 mM siRNA stocks were diluted in OptiMEM and
Lipofectamine2000 and were added to cells at a 10 nM final
concentration. For microarrays, cells were treated with cdr2 or
Figure 7. Cdr2 knockdown causes impaired proliferation. Steady state proliferation (
3H-thymidine incorporation (cpm)) of HeLa (A) and MCF7
(B) cells after control or cdr2 siRNA treatment. *p,0.05. C. HeLa
3H-thymidine incorporation (cpm) time course in cells released from G1/S block;
*p,0.05, **p,0.005.
doi:10.1371/journal.pone.0010045.g007
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harvested RNA 3 hours after release from a mitotic block.
Luciferase assays were done using a luciferase assay kit (Promega).
Activity was calculated by normalizing raw firefly luciferase
activity to GFP expression levels measured by western blot. For
proliferation assays, cells were plated in 96-well plates, labeled for
6 hours with
3H-thymidine (GE Healthcare) and harvested on a
Unifilter96 GF/C filter and counted on a TopCount machine
(PerkinElmer). Cycloheximide stocks were diluted to 35 mg/ml for
protein stability studies.
Viral transduction
T7cdr2 cDNA was cloned into pCXiBSR. pCXiBSR alone and
pCX-T7cdr2iBSR were transfected into HEK293 to produce
retroviruses [58]. Supernatants were used to transduce NIH3T3
cells; transduced cells were selected with 20 mg/ml blasticidin
(Invitrogen), which killed all non-infected cells. Blasticidin-resistant
cells were expanded and T7cdr2 expression was confirmed by
western blot and immunocytochemistry.
Flow Cytometry
We stained cells with TOPRO3 (Invitrogen) to measure DNA
content. Cells were harvested by trypsinization, rinsed and re-
suspended in PBS/2 mM EDTA, fixed by addition of cold 70%
ethanol. Cells were spun at 1000 rpm for 5 minutes, 4uC and then
re-suspended in 0.5 ml staining solution (950 ml PBS/2 mM
EDTA, 20 ml RNaseA (10 mg/ml; Clontech), TOPRO3
(0.4 mM)). Reactions were incubated at 37uC for 30 minutes then
Figure 8. Cdr2 overexpression in tumors drives the cell cycle. A. Western blots of EL4 and EC2-1 extracts probed with cdr2 and c-tubulin
antisera (left) and steady state proliferation (
3H-thymidine incorporation (cpm)) of EL4 or EC2-1 cells lines (right); *p,0.05. B. Quantitation of tumor
size (cm
2) in EL4- (black) and EC2-1- (gray) injected nude mice at indicated days. C. Western blots of tumor extracts from mice injected with EL4 or
EC2-1 cells probed with cdr2 and c-tubulin antisera. D. Representative hematoxylin and eosin stains of EL4 (left) or EC2-1 (right) tumor sections (60X).
Black arrowheads indicate mitotic figures; clear arrowheads indicate apoptotic figures. Scale bar=10 mm. E. Quantitation of mitotic figures. *p,0.05.
F. Quantitation of apoptotic figures; *p,0.05.
doi:10.1371/journal.pone.0010045.g008
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performed with Cell Quest (BD Biosciences) and FlowJo software.
Microarray
RNA for microarrays was harvested using the RNeasy kit. RT,
second strand synthesis, cDNA purification and in vitro transcrip-
tion with Biotin-11-UTP were performed using the MessageAmp
II aRNA Amplification Kit (Ambion). Hybridization of the aRNA
to Affymetrix Human Genome U133 Plus 2.0 Arrays was carried
out by the Rockefeller University Genomics Resource Center.
Data was analyzed using GenespringGX software version 7.3.1
(Agilent). We performed 1-way ANOVA without multiple testing
correction, p,0.01 to identify transcripts 1.5-fold differentially
regulated between control and cdr2 siRNA treated cells in
biological triplicate and eliminated transcripts below raw expres-
sion levels of 100 (arbitrary units). Microarray data (GSE20037)
has been submitted to the Gene Expression Omnibus.
Antibodies
Anti-cdr2/3 (Yo) antibodies are derived from PCD patient sera
and CSF. Cdr2 monoclonal (4F5) is from Abnova. Cdr2 rabbit
polyclonal is from Novus (NB110-58345). CyclinB1 (C8831), c-
tubulin (GTU88), HA (H6908), and c-myc (9E10 (mouse) and
C3956 (rabbit)) antibodies are from Sigma. a-tubulin (DM1A),
APC11, Cdc23 and APC1 antibodies are from Abcam. Anti-T7 is
from Novagen. Horseradish peroxidase (HRP)-conjugated Anti-HA
(3F10) is from Roche. Anti-Cdc27 (AF3.1) was a gift from Julian
Gannon (Clare Hall Labs, Cancer Research UK). c-myc antibody
(9402) is from Cell Signaling Technology. Anti-GFP (JL8) is from
Clontech. Mouse, rabbit and human HRP- and FITC/Cy5-
conjugated antibodies are from Jackson. Mouse, rabbit and human
Alexa488/594/647-conjugated antibodies are from Invitrogen.
Western blot and Immunocytochemistry
Western blots were performed as previously described [59,60]
and were quantitated using a Versadoc imaging system (BioRad).
Cells were plated on collagen-coated slides (BD Biosciences).
Cells were rinsed in PBS, fixed with 3.7% paraformaldehyde in
PBS (pH 7.4) for 15 minutes; permeabilized in 0.5% NP-40/PBS
for 20 minutes; blocked in 0.2% gelatin/0.5% bovine serum
albumin/PBS for 20 minutes, all at room temperature. Antibodies
were diluted in block buffer and incubated overnight at 4uC.
Fluorescent secondary antibodies were diluted in block buffer and
incubated for 30 minutes at room temperature. Cells were rinsed
with PBS. DAPI (49,6-Diamidino-2-phenylindole dihydrochloride;
Sigma) was included in the final wash before cover-slipping with
GelMount (Biomeda). Slides were viewed on a Zeiss Axioplan
microscope. Images were captured with a Hamamatsu Digital
Camera. Image processing was performed using AxioVision 4.4
(Zeiss). Confocal laser scanning microscopy images were collected
at the Bio-Imaging Resource Center at Rockefeller University with
a Zeiss Axiovert200 microscope and LSM510 META version 3.2
software.
We identified mitotic spindles using DAPI and a-tubulin
immunofluorescence. Prior to fixation in 4% formaldehyde
(pH 6.9) with 100 mM K-PIPES, 1 mM MgCl2, 0.1 mM CaCl2
and 0.1% Triton X-100, cells were incubated at 37uCi n
microtubule stabilizing buffer (4M glycerol, 100 mM K-PIPES
(pH 6.9), 1 mM EGTA, 5 mM MgCl2, 0.5% Triton X-100).
.750 cells were counted for each condition.
In vitro ubiquitination and degradation assay
35S-Met (GE Healthcare)-T7cdr2 was synthesized using a rabbit
reticulocyte lysate (Promega). Human E1, UbcH5b (E2), ubiquitin
and ubiquitin aldehyde are from Boston Biochem. The ubiquiti-
nation reaction consisted of
35S-T7cdr2, APC/C, HACdc20 or
HACdh1, and 500 nM E1, 1.5 mM UbcH5b, ATP buffer
(0.4 mM ATP pH 7.4, 3 mM creatine phosphate, 40 mM EDTA,
pH 7.7), 15 mg ubiquitin, 2 mM ubiquitin aldehyde and was
incubated at 30uC for 1 hour with aliquots taken at 0, 20 and 60
minutes and placed in Laemmli sample buffer (BioRad) and boiled
for 4 minutes.
The APC/C was immunopurified from HEK293 cells released
for 4 hours from a mitotic block. Cells were harvested in Swelling
Buffer (20 mM HEPES, pH 7.5, 5 mM MgCl2 5 mM KCl, ATP
buffer, and a protease inhibitor cocktail (Calbiochem)). Cells were
rapidly freeze-thawed in ethanol/dry ice and a 37uC water bath
before passing through an ice-cold 18-gauge needle. Cells were
Figure 9. Model of cdr2 action in mitosis. Cdr2 levels increase in
G2, peak in mitosis and decrease as cells exit mitosis. Nuclear envelope
breakdown in prometaphase allows newly synthesized cdr2 access to c-
myc protein, which, like other transcription factors [61], partitions itself
off DNA during chromatin condensation, coinciding with mitotic
shutdown of transcription. Cdr2 colocalization with c-myc is first
apparent during metaphase (Figs. 4C, 5D) and peaks during telophase/
cytokinesis (Fig. 4F) after which c-myc relocalizes to the nucleus
(Figs. 4D, 5E). During late mitosis/early G1, cdr2 KEN and D boxes are
recognized by the APC/C, which ubiquitinates cdr2, targeting it for
degradation by the proteasome. Cdr2 knockdown cells show defects in
mitotic spindle formation, cell cycle progression and c-myc-dependent
transcription. Based on our current results, and the observations that
cdr2 is preferentially phosphorylated during G1 but not mitosis [51],
and that a smaller migrating, possibly dephosphorylated, isoform of
cdr2 interacts with c-myc in vivo [11], we hypothesize that unpho-
sphorylated cdr2 interacts with c-myc to prevent c-myc degradation,
thereby allowing subsequent c-myc-dependent transcription of genes
to occur upon resumption of transcription following mitosis. At this
point phosphorylation of cdr2 leads to recognition by the APC/C,
targeting it for degradation by the proteasome. In tissue culture,
overexpression of cdr2 may lead to several effects, including aberrant
sequestration of c-myc and inhibition of c-myc activity [11]. Taken
together, the data suggest an overall hypothesis, in which that cdr2
action on c-myc leads to a concerted action on target genes to promote
cellular proliferation, and that this action is inhibited by cdr2
knockdown. Disruption of cdr2:c-myc control may therefore disrupt
mitotic exit and impact the growth of cdr2-expressing tumors.
doi:10.1371/journal.pone.0010045.g009
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and re-spun at 4uC, 14,000 rpm for 25 minutes. Supernatants
were used as input for the APC/C (anti-Cdc27) immunoprecip-
itation. Following a 3 hour incubation at 4uC, Protein A beads
(Sigma) were added for 1 hour. IP’s were washed with swelling
buffer/1% TritonX-100 and with swelling buffer. Purified APC/C
was added on beads to the ubiquitination reaction. HACdc20 and
HACdh1 were expressed in and purified from HEK293 cells using
an HA antibody. Immunoprecipitated HACdc20 or HACdh1
were added on beads to the ubiquitination reaction.
35S-T7cdr2
was immunoprecipitated from rabbit reticulocyte lysates with anti-
T7 and was added on beads to the ubiquitination reaction.
35S-labeled-T7cdr2, T7cdr2KEND1/D2 and cyclinB1 were
synthesized in vitro using rabbit reticulocyte lysates and incubated
with mitotic release HEK293 extracts which were prepared as
described for the in vitro ubiquitination reaction. Reaction
conditions were the same as for the ubiquitination reaction.
Nude Mice Tumor Experiments
Stable cdr2-expressing EL4 cells (EC2) were derived following
transfection of a cdr2 expression vector with G418 resistance and
selection in G418. Cells were harvested, rinsed and counted with a
hemocytometer before re-suspension at 10
7 cells/ml. 10
6 cells
(100 ml) were injected into the left flank of 5 athymic nude mice
(NU/J (Jackson Labs)) for each line. 5 control mice were injected
with DMEM alone. Prior to injection, mice were anaesthetized
with isofluorane (Baxter). Tumor size was measured daily (length
and width) from the first sign of tumor growth. Animals were
euthanized at two weeks post-injection or sooner if tumor size
exceeded 5 cm
2. Tissue was processed for western blot and
histopathology, which was performed by the Research Animal
Resource Center at Cornell University. Mitotic and apoptotic
figures were quantitated by counting their total numbers per 60X
section, 3 sections for each animal for a total of 10 animals with
the counter blind to the cell line.
Ethics Statement
All animals were handled in accordance with animal husbandry
guidelines established and reviewed by the Rockefeller University
Institutional Animal Care and Use Committee (IACUC), which
comply with federal and state regulations that concern the use of
experimental animals.
Supporting Information
Table S1 The table lists GO term enrichment from the cdr2-
regulated gene data set in HeLa cells exiting mitosis.
Found at: doi:10.1371/journal.pone.0010045.s001 (0.02 MB
XLS)
Table S2 Cdr2-regulated gene list. Genes are categorized by
Affymetrix ID, fold change (value ,1 indicates down-regulation;
value .1, up-regulation) and gene description. The first list (Sheet
1) is of all 390 cdr2-regulated Affymetrix ID genes, the second list
(Sheet 2) is 324 Affymetrix IDs and is the same as the first list
except duplicate genes have been removed.
Found at: doi:10.1371/journal.pone.0010045.s002 (0.10 MB
XLS)
Table S3 This table lists all the primers used in this paper.
Found at: doi:10.1371/journal.pone.0010045.s003 (0.04 MB
XLS)
Figure S1 A. Cdr2 and cyclinB1 mRNA levels in HeLa cells at
0, 4, 8 and 12 hours after G1/S release, measured by qRT-PCR
(normalized to b-actin mRNA). *p,0.01. B. Top, cdr2 (NB110)
and a-tubulin western blots of cycloheximide-treated HeLa cells at
indicated times; bottom, quantitation of cdr2 and tubulin levels at
indicated times. C. Anti-T7 western blot of input and T7 or
control (GFP) immunoprecipitations of T7cdr2-transfected
HEK293 treated with DMSO or MG132 for six hours.
Found at: doi:10.1371/journal.pone.0010045.s004 (0.99 MB TIF)
Figure S2 A. Anti-T7 western of input and T7 immunoprecip-
itates from T7cdr2 (top) and T7cdr2 KEN/D1D2 (bottom)
transfected HEK293s. B. Anti-cdc27 immunoprecipitation and
western blot with cdc27, cdc23 and APC11 antisera of HEK293s
exiting mitosis. C. APC/C in vitro ubiquitination of 35S-cyclinB1
and 35S-Nova1. D. Anti-HA western of HA immunoprecipitation
and inputs of HACdc20 and HACdh1 expressing HEK293s.
Found at: doi:10.1371/journal.pone.0010045.s005 (0.87 MB TIF)
Figure S3 A. Western blot of HeLa extracts transfected with
control and cdr2 siRNA pools probed with anti-cdr2 (4F5) and
anti-c-tubulin, showing triplicate experiments. ns indicates non-
specific immunoreactive band detected by anti-cdr2 (4F5). B. Flow
cytometry of G1S-arrested (top) and G1S-released (12 hour
release, bottom) HeLa cells treated with control (left) or cdr2
siRNA pools (right) and stained with TOPRO3 to measure DNA
content.
Found at: doi:10.1371/journal.pone.0010045.s006 (0.60 MB TIF)
Figure S4 A. qRT-PCR of cdr2 mRNA levels (normalized to
GAPDH mRNA) in Rat-1 wild type (left) and Rat-1 c-myc null
cells (right) treated with control or rat cdr2 siRNA pools.
Found at: doi:10.1371/journal.pone.0010045.s007 (0.16 MB TIF)
Figure S5 A. NIH3T3 steady state proliferation (3H-thymidine
incorporation (cpm)) in stable cell lines expressing control (empty
vector) or T7cdr2, *p,0.0001. B. Primary cerebellar granule cell
neuron (GCN; 2DIV) steady state proliferation (3H-thymidine
incorporation (cpm)) in cells transduced with control or T7cdr2
expressing virus. *p,0.005.
Found at: doi:10.1371/journal.pone.0010045.s008 (0.36 MB TIF)
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